The Value of Medicines and Vaccines to Irish patients and the Irish economy
IPHA Healthcare Facts And Figures 2009
Newsletter Banca IFIS Group 10
Greece—Memorandum of Understanding on Specific Economic Policy Conditionality, 9 Feb 2012
Primary Care and Economic Crisis
Can We Keep Pharmaceutical Costs Affordable and New Medicines Development Viable? A P.B.S. Perspective Can We Keep Pharmaceutical Costs Affordable and.
Presentation by Ganesh Nayak, COO and Executive Director, Zydus Cadila.
Improving access to generic & biosimilar medicines in Bulgaria and in the EU 1 Adrian van den Hoven Director General EGA – European Generic medicines Associations.
Deloitte Center for Health Solutions Evidence-based Medicine and Disease Management: Strategic Context, Emerging Implications Paul H. Keckley, Ph.D. Associate.
Health Policy Issues on Rare Diseases in Korea
Evidence-based Medicine and Disease Management: Strategic Context, Emerging Implications